Leading Tech Analyst Previews Earnings for Anadigics, Integrated Device Technology, International Rectifier, Cavium, and Flextronics

Apr 29, 2013, 10:08 ET from Indie Research Advisors, LLC

PRINCETON, N.J., April 29, 2013 /PRNewswire/ -- Next Inning Technology Research (http://www.nextinning.com), an online investment newsletter focused on technology stocks, has issued updated outlooks for Anadigics (Nasdaq: ANAD), Integrated Device Technology (Nasdaq: IDTI), International Rectifier (NYSE: IRF), Cavium (Nasdaq: CAVM), and Flextronics (Nasdaq: FLEX).

During 2012, Next Inning editor, Paul McWilliams predicted both the spring and fall corrections as well as the rally that started in November and carried through the first quarter of 2013.  On the day the November rally started, he advised readers it would lift the NASDAQ by as much at 18% by the end of March 2013.  As we know now, that is exactly what happened. 

To keep Next Inning readers ahead of the curve, Next Inning is now publishing McWilliams' highly acclaimed earnings previews.  These reports outline McWilliams' outlook for the second quarter and provide readers with deep insight into the world's leading tech companies.  McWilliams also shares his opinions as to which of these companies investors should buy and which should be avoided.

Trial subscribers will also receive McWilliams' 167-page State of Tech report, which includes 35 detailed tables and graphs, for free, no strings attached. This report is a must read for investors and analysts focusing on technology in 2013.

Already in 2013, McWilliams suggested buying several including Cree (up 62% year to date), Micron (up 49% year to date), Marvell (up 45% year to date), and SanDisk (up 24% year to date). Stocks he suggested avoiding/selling include Netlist (down 28% year to date), Fairchild (down 13% year to date) and Cypress (down 8% year to date). McWilliams' new earnings previews outline which stocks investors will want to own and which they should avoid.

To get ahead of the Wall Street curve and receive McWilliams' Q1 2013 State or Tech report, you are invited to take a free, 21-day, no obligation trial with Next Inning.  For full details on this offer, please visit the following link:


Topics discussed in the latest reports include:

-- Anadigics: What leads McWilliams to forecast Anadigics will imply, if not guide for, a strong double digit revenue increase in calendar Q2 and that the company will report revenue comfortably above $40M in Q4 2013?  How does McWilliams think Anadigics will use the funds it raised via a secondary offering last quarter?  What smartphone models are now using Anadigics' technology? What three hurdles must Anadigics clear that will lead to a notably higher price for the stock?

-- IDT: McWilliams suggested that Next Inning readers buy IDT in his Q3 2012 State of Tech report at the then current price of $5.87 and then, six months later in his Q1 2013 State of Tech report, he wrote it was time to sell when IDT was trading at $7.47.  Since then, the price of IDT has dropped over 8%.  How is IDT positioned in the PCIe switch market, and why might this market see stronger-than-expected growth?  Do IDT shares have significant upside potential if IDT executes in line with its strategy and Wall Street begins to better recognize the new story at the company?  Does McWilliams think it is time to jump back in?

-- International Rectifier: Have the issues negatively impacting International Rectifier during the past couple of years been company-specific, market-specific or a combination of both?  What event pushed the price of International Rectifier up from its recent low in the $17s?  At what price should investors consider adding shares of the stock, and what is McWilliams' target price?

-- Cavium: In his Q1 2013 State of Tech report, McWilliams strongly suggested selling shares of Cavium.  According to McWilliams, it's not Cavium's growth prospects that should concern investors, it's the quality of Cavium's earnings.  Since that report was published, the price of Cavium has dropped 23%.  What specific issues does McWilliams take with Cavium's non-GAAP earnings presentation and what evidence does he point to on Cavium's balance sheet and cash flow statement to support his opinions.  Is Cavium likely to face increased competitive threats going forward? With Cavium shares now sharply lower, does McWilliams believe Cavium is due for a rebound or does he think the price is destined to sink lower?

-- Flextronics:  What caused McWilliams to adjust his rating on Flextronics last year? Has McWilliams taken a more bullish or bearish view of Flextronics? Does McWilliams expect that Flextronics will outperform expectations this year?  Why does McWilliams claim that investors should consider the potential return on invested capital (ROIC) Flextronics will earn from its newly signed deal to take over manufacturing for Motorola Mobility?  What is his price target for Flextonics?  Trial subscribers will have full access to McWilliams' highly acclaimed "Paradigm Paper" covering the EMS sector.

Founded in September 2002, Next Inning's model portfolio has returned 241% since its inception versus 74% for the S&P 500.

About Next Inning: Next Inning is a subscription-based investment newsletter that provides regular coverage on more than 150 technology and semiconductor stocks.  Subscribers receive intra-day analysis, commentary and recommendations, as well as access to monthly semiconductor sales analysis, regular Special Reports, and the Next Inning model portfolio. Editor Paul McWilliams is a 30+ year semiconductor industry veteran.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926.  Interested parties may visit adviserinfo.sec.gov for additional information.  Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin, Next Inning Technology Research, +1-888-278-5515

SOURCE Indie Research Advisors, LLC